secwatch.observer — SEC 8-K summary
======================================

Issuer:     QUEST DIAGNOSTICS INC (DGX)
CIK:        0001022079
Form:       8-K
Filed at:   2023-03-17T23:59:59+00:00
Accession:  0000947871-23-000333
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quest Diagnostics updates 2023-2026 outlook: mid single-digit revenue CAGR, high single-digit adjusted EPS CAGR
--------------------------------------------------------------------------------

- Reiterates 2023 guidance: revenue $8.83B-$9.03B, base business +2.6%-3.8%, adjusted EPS $8.40-$9.00.
- Long-term 2023-2026: mid single-digit revenue CAGR; high single-digit adjusted EPS CAGR.
- Invigorate program targets ~3% annual productivity savings via automation, AI, and digital.
- Growth initiatives: physician/hospital expansion, molecular genomics, oncology, consumer health.
- No change to 2023 guidance; capital deployment strategy discussed without new commitments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022079/000094787123000333/0000947871-23-000333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022079/000094787123000333/ss1867887_8k.htm
  HTML page:      https://secwatch.observer/filing/0000947871-23-000333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer